The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 11, 2022
Filed:
Dec. 16, 2016
Amgen Inc., Thousand Oaks, CA (US);
Medimmune, Llc, Gaithersburg, MD (US);
Robert W. Georgantas, III, Gaithersburg, MD (US);
Chris Morehouse, Gaithersburg, MD (US);
Brandon Higgs, Gaithersburg, MD (US);
Koustubh Ranade, Gaithersburg, MD (US);
Katie Streicher, Gaithersburg, MD (US);
William Rees, Thousand Oaks, CA (US);
Meina Liang, Gaithersburg, MD (US);
Raffaella Faggioni, Gaithersburg, MD (US);
Jing Li, Gaithersburg, MD (US);
Inna Vainshtein, Gaithersburg, MD (US);
Yen-Wah Lee, Gaithersburg, MD (US);
Jingjing Chen, Gaithersburg, MD (US);
Robert A. Gasser, Jr., Gaithersburg, MD (US);
AMGEN INC., Thousand Oaks, CA (US);
MEDIMMUNE, LLC, Gaithersburg, MD (US);
Abstract
The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).